EURO-ccraft: EUROpean Coronary microCirculatory Resistance and Absolute Flow Trial

Sponsor
Catharina Ziekenhuis Eindhoven (Other)
Overall Status
Recruiting
CT.gov ID
NCT04598308
Collaborator
Onze Lieve Vrouwziekenhuis Aalst (Other)
200
1
36
5.6

Study Details

Study Description

Brief Summary

Rationale: coronary microvascular disease is a relatively 'new' entity within the field of cardiology. The investigators are able to investigate the microcirculation by measurements performed in the catheterization laboratory. But even though measurements are performed on a daily basis, a lot of questions regarding microvascular disease remain. The rationale of this registry is to get an overview of patients and measurement values in daily routine practice.

Objective and main endpoint: No previous registries have been set-up where coronary blood flow and resistance was systematically stored. Therefore the analyses will be mainly descriptive. The objective is to acquire a better insight in the indications and use of this technique in everyday practice , its consequences for clinical decision making, and to enable interventionalists to exchange mutual knowledge about this specific methodology and about the coronary microcirculation in general.

Study design: prospective registry

Study population: All patients who underwent coronary angiography with or without coronary intervention for any reason and if an indication for the foreseen intracoronary physiologic measurements is present according to the discretion of the operator.

Intervention (if applicable): none, only usage of measurement data. The only 'intervention' for all patients is a questionnaire.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: absolute flow and resistance measurements

Detailed Description

This registry only collects all measurement data from normal/routine physiologic assessment in the cathlab. These measurements are performed on a daily basis. The following paragraph will explain these routine measurements briefly.

Short description of the procedure Coronary angiography, PCI (if indicated), and physiologic measurements are performed completely according to normal routine. Physiologic measurements may include FFR, NHPR, IMR, CFR, absolute flow (Q) and microcirculatory resistance (Rmicro or MRR) measurement.

Intention to measure Q and Rmicro are mandatory to be included in this registry.

If there is failure to measure Q and/or Rmicro , it should be carefully noted including the reason for failure.

Coronary physiologic measurements may be performed either prior or after PCI, if applicable. If they are performed before PCI, it is recommended (according to Good Clinical Practice) but not absolutely mandatory to repeat these measurements also after PCI.

As said, the invasive procedure itself, including all measurements, should be performed completely according to clinical routine. Use of drugs either during or after the procedure should also exactly identical to normal routine.

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
200 participants
Observational Model:
Other
Time Perspective:
Prospective
Official Title:
EUROpean Coronary microCirculatory Resistance and Absolute Flow Trial: An European Registry
Actual Study Start Date :
Oct 1, 2020
Anticipated Primary Completion Date :
Oct 1, 2022
Anticipated Study Completion Date :
Oct 1, 2023

Arms and Interventions

Arm Intervention/Treatment
patients undergoing invasive assessment of the microcirculation

All patients are eligible for participation in this registry if they are undergoing coronary angiography with or without coronary intervention for any reason and if an indication for the foreseen intracoronary physiologic measurements is present according to the discretion of the investigating operator. There are no specific exclusion criteria other than contraindications for physiologic measurements in general.

Diagnostic Test: absolute flow and resistance measurements
This registry only collects all measurement data from normal/routine physiologic assessment in the cathlab. These measurements are performed on a daily basis Short description of the procedure Coronary angiography, PCI (if indicated), and physiologic measurements are performed completely according to normal routine. Physiologic measurements may include FFR, NHPR, IMR, CFR, absolute flow (Q) and microcirculatory resistance (Rmicro or MRR) measurement. Intention to measure Q and Rmicro are mandatory to be included in this registry. Use of drugs either during or after the procedure should also exactly identical to normal routine.

Outcome Measures

Primary Outcome Measures

  1. clinical treatment assessment [1 year]

    change in clinical decision making after invasive assessment of the microcirculation

Secondary Outcome Measures

  1. IMR and resistance measurement [2 years]

    comparison between IMR and microvascular R measurements in WU

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 90 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion criteria:
  • All patients are eligible for participation in this registry if they are undergoing coronary angiography with or without coronary intervention for any reason and if an indication for the foreseen intracoronary physiologic measurements is present according to the discretion of the investigating operator.

  • 18 and <90 years of age

  • able to give informed consent

Exclusion criteria:
  • There are no specific exclusion criteria other than contraindications for physiologic measurements in general.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Catharina Hospital Eindhoven Brabant Netherlands 5623EJ

Sponsors and Collaborators

  • Catharina Ziekenhuis Eindhoven
  • Onze Lieve Vrouwziekenhuis Aalst

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Danielle Keulards, Principal investigator, Catharina Ziekenhuis Eindhoven
ClinicalTrials.gov Identifier:
NCT04598308
Other Study ID Numbers:
  • NL74650.100.20
First Posted:
Oct 22, 2020
Last Update Posted:
Oct 22, 2020
Last Verified:
Oct 1, 2020
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Danielle Keulards, Principal investigator, Catharina Ziekenhuis Eindhoven
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 22, 2020